Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, is engaged in the research and development, manufacture and marketing of pharmaceuticals for inflammatory and immune-related diseases. The company is headquartered in Markham, Canada.
52W High
$5.00
52W Low
$1.55
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.10
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
0.17
EV/EBITDA (<8 favorable)
-1.25
EV/Revenue (<3 favorable)
128525.38
P/S (TTM) (<3 favorable)
120477.93
P/B (<3 favorable)
3.63
Ownership
BalancedSource: Overview
Insiders (1–5% typical)
28.55%
Institutions (25–75% balanced)
29.96%
Shares Outstanding
7,037,600
Float
4,282,600
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
500
Gross Profit (TTM)
311,200
EPS (TTM)
-1.24
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.70%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentumValue
0.0528
Previous
0.0598
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025